Methods and systems for identifying and treating anti-progestin sensitive tumors

Abstract

Methods and systems for identifying and treating a patient suspected of having a tumor susceptible to growth inhibition by anti-progestins are provided. The degree of focal distribution of the progesterone receptor can be used to identify tumors susceptible to treatment with anti-progestin therapy.

1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . (canceled) 
     
     
         19 . (canceled) 
     
     
         20 . (canceled) 
     
     
         21 . A method of inhibiting the growth of a tumor susceptible to growth inhibition by anti-progestins, comprising:
 a) obtaining a tissue sample suspected of being tumorigenic or cancerous from a patient;   b) identifying progesterone receptor positive cells in the tissue sample;   c) determining the degree of focal distribution of the progesterone receptor in nuclei of the progesterone positive cells from the tissue sample and identifying the antibody binding pattern of the progesterone positive cells of tissue; and   d) administering an anti-progestin to the patient if the degree of focal distribution in the tissue sample is greater than about 5% of the progesterone receptor positive cells.   
     
     
         22 . The method of  claim 1 , further comprising determining the degree of focal distribution in nuclei in cells from the tissue by exposing the tissue to anti-progesterone receptor antibodies. 
     
     
         23 . The method of  claim 1 , wherein the tumor is selected from the group consisting of breast, brain, meningiomas, prostate, ovarian, endometrial, uterine leiomyoma, lung, and uterine tissue. 
     
     
         24 . The method of  claim 1 , wherein the binding pattern is selected from group consisting of diffuse (D), active (A), and active/diffuse (AD). 
     
     
         25 . The method of  claim 2 , wherein at least two antibodies are used to determine the degree of focal distribution. 
     
     
         26 . The method of  claim 2 , wherein the antibodies are selected from the group consisting of anti-PR-A antibody, anti-PR-B antibody, and a mixture of anti-PR-A and anti-PR-B antibodies, and bi-specific antibodies related to PR-A and PR-B. 
     
     
         27 . The method of  claim 2 , wherein the degree of focal distribution of the progesterone receptor is determined by a detection method selected from the group consisting of immunohistochemistry, immunofluorescence, and Western blot. 
     
     
         28 . The method of  claim 1 , wherein the anti-progestin is administered to the patient in an amount from about 10 mg to about 200 mg per day. 
     
     
         29 . A method of treating a patient with a tumor susceptible to growth inhibition by anti-progestins, comprising:
 a) obtaining a tissue sample suspected of being tumorigenic from a patient;   b) exposing the tissue to an anti-progesterone receptor antibody;   c) identifying progesterone receptor positive cells in the tissue sample and identifying the binding pattern of the progesterone positive cells of the tissue;   d) determining the focal binding distribution of the progesterone receptor in nuclei of cells from the tissue and identifying the binding pattern of the progesterone positive cells of the tissue, wherein if the focal binding distribution is greater than 5% of the progesterone receptor positive cells in the tissue sample with an A or AD binding pattern, an anti-progestin is administered to the patient in a dosage range of about 10 to about 200 mg per day.   
     
     
         30 . The method of  claim 9 , wherein the tumor is selected from the group consisting of breast, brain, meningiomas, prostate, ovarian, endometrial, uterine leiomyoma, lung, and uterine tissues. 
     
     
         31 . The method of  claim 9 , wherein the binding pattern is selected from group consisting of diffuse (D), active (A), and active/diffuse (AD). 
     
     
         32 . The method of  claim 11 , wherein the antibody is selected from the group consisting of anti-PR-A antibody, anti-PR-B antibody, a bi-specific antibody directed to PR-A and PR-B, and a mixture of anti-PR-A and anti-PR-B antibodies.